MARKET

REXN

REXN

REXAHN PHARMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.870
+0.010
+0.54%
Closed 19:43 11/12 EST
OPEN
1.860
PREV CLOSE
1.860
HIGH
1.940
LOW
1.825
VOLUME
7.14K
TURNOVER
--
52 WEEK HIGH
19.80
52 WEEK LOW
1.590
MARKET CAP
7.52M
P/E (TTM)
-0.4372
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of REXN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

REXN News

  • Rexahn up 52% on encouraging RX-5902 data
  • Seeking Alpha - Article.11/01 16:54
  • ANET, PINS, CRC and REXN among midday movers
  • Seeking Alpha - Article.11/01 16:41
  • Rexahn Pharma Shares Down 11% From Session High But Still Up 49% For Session; Data Highlighted In 'Molecular Cancer Therapeutics' Nov. Issue Was Previously Reported On Sep. 5, 2019
  • Benzinga.11/01 15:53
  • Rexahn Pharma Shares Up 33%; Traders Recently Circulate Data Published In Molecular Cancer Therapeutics 'RX-5902 Inhibits ß-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer'
  • https://twitter.com/BioRunUp/status/1190289991693262848.11/01 15:37

More

Industry

Biotechnology & Medical Research
+0.45%
Pharmaceuticals & Medical Research
+0.31%

Hot Stocks

Name
Price
%Change

About REXN

Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.
More

Webull offers Rexahn Pharmaceuticals, Inc. (REXN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.